Achilles Therapeutics (ACHL) PT Lowered to $17 at Chardan Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ACHL Hot Sheet
Price: $1.48 --0%
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Chardan Capital Markets analyst Geulah Livshits lowered the price target on Achilles Therapeutics (NASDAQ: ACHL) to $17.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- Befesa SA (BFSA:GR) PT Raised to EUR41 at Deutsche Bank
- Ariston Holding NV (ARIS:IM) PT Lowered to EUR4.50 at Citi
- UPM-Kymmene OYJ (UPM:FH) (UPMKY) PT Lowered to EUR20 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
